1. 19LBA Docetaxel (Doc) +/− zoledronic acid (ZA) for hormone-naive prostate cancer: First overall survival results from STAMPEDE & treatment effects within subgroups (NCT00268476). Issue 3 (September 2015) Authors: James, N.D.; Sydes, M.R.; Mason, M.D.; Clarke, N.W.; Dearnaley, D.P.; Spears, M.R.; Millman, R.; Parker, C.C.; Ritchie, A.W.S.; Russell, J.M.; Staffurth, J.; Jones, R.J.; Cathomas, R.; Robinson, A.; Chowdhury, S.; Tsang, D.; Brock, S.; Parikh, O.; Graham, J.D.; Parmar, M.K.B. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S719 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Response to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et al. Issue 10 (October 2016) Authors: James, N.D.; Sydes, M.R.; Clarke, N.W.; Ritchie, A.W.S.; Parmar, M.K.B. Journal: Clinical oncology Issue: Volume 28:Issue 10(2016) Page Start: 666 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗